Compared to a control (left), a soluble version of TLR5 (right) reduces the...
Compared to a control (left), a soluble version of TLR5 (right) reduces the formation of amyloid plaques (brown) in the brains of mice that produce large amounts of human β-amyloid.

 Credit: Chakrabarty et al., 2018

News • Neurology

New potential biotherapy against Alzheimer's disease

Researchers at the University of Florida have discovered that a modified version of an important immune cell protein could be used to treat Alzheimer's disease. The study reveals that soluble versions of a protein called TLR5 can reduce the buildup of amyloid plaques in the brains of Alzheimer's disease model mice and prevent the toxic peptide that forms these plaques from killing neurons.

Alzheimer's disease is characterized by the formation of amyloid plaques containing aggregates of a toxic protein fragment called β-amyloid that causes nerve cells in the brain to degenerate and die. The body's immune system can influence the progression of Alzheimer's disease by, on the one hand, reducing the buildup of β-amyloid or, on the other, responding to neuronal damage by inducing inflammation that can lead to further neurodegeneration.

Toll-like receptors (TLRs) are a family of proteins on the surface of immune cells that recognize molecules released by pathogens or damaged cells and then initiate an appropriate immune response. A team of researchers at the University of Florida led by Paramita Chakrabarty and Todd E. Golde found that the brains of Alzheimer's disease patients had more TLRs, partly due to an increase in the number of specialized brain immune cells known as microglia.

The researchers hypothesized that untethering some of these TLRs from the surface of microglia could reduce the formation of amyloid plaques. These soluble TLRs might act as "decoy receptors" that bind to β-amyloid and limit its aggregation without initiating cellular signaling pathways that could lead to inflammation.

Chakrabarty and colleagues found that soluble versions of one TLR in particular—TLR5—could prevent or even reverse the formation of amyloid plaques in mice that produce large amounts of human β-amyloid. "This mouse model is well recognized as a primary model for Alzheimer-type amyloid plaque deposition, but it does not recapitulate the entire Alzheimer's neurodegenerative cascade," says Chakrabarty. "Therefore, the potential of soluble TLR5 in dampening immune activation and related neurotoxic pathways needs to be further explored in multiple models of Alzheimer's disease."

The researchers determined that soluble TLR5 could bind to β-amyloid aggregates and enhance their uptake into microglia. It also reduced the ability of β-amyloid to kill neurons cultured in the laboratory. "By directly interacting with β-amyloid and attenuating β-amyloid levels in mice, the soluble TLR5 decoy receptor represents a novel and potentially safe class of immunomodulatory agents for Alzheimer's disease," says Golde.

Source: Rockefeller University Press

31.08.2018

Read all latest stories

Related articles

Photo

News • Opening the blood-brain barrier

3D-printed acoustic holograms against Alzheimer's or Parkinson's

A research team in Spain and the US has created 3D-printed acoustic holograms to improve the treatment of diseases like Alzheimer's and Parkinson's, among others.

Photo

News • Neurodegeneration

The importance of the liver-brain axis in Alzheimer's disease

A research team from Barcelona studied the liver of Alzheimer's disease mice models, and demonstrated the importance of the liver-brain axis regarding the psychological symptoms of the disease.

Photo

News • Neuroscience & Alzheimer's disease

Researchers identifiy subset of neurons that are most susceptible to Alzheimer's disease

Neurodegeneration, or the gradual loss of neuron function, is one of the key features of Alzheimer's disease. However, it doesn't affect all parts of the brain equally.

Related products

Alphenix Biplane High Definition Detector

Bi-Plane

Canon · Alphenix Biplane High Definition Detector

Canon Medical Systems Europe B.V.
Magnetom Amira

1.5 Tesla

Siemens Healthineers · Magnetom Amira

Siemens Healthcare GmbH
Sarstedt – CSF false-bottom tube

CSF and Alzheimer’s Disease Diagnostics

Sarstedt – CSF false-bottom tube

SARSTEDT AG & CO. KG
Vitrea Advanced Visualization

Reading

Canon · Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Subscribe to Newsletter